Back
ESC Premium Access

Major bleeding among patients with atrial fibrillation treated with rivaroxaban or warfarin in Sweden. Interim results from an on-going post-authorization study

Session: Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?
Topic: Medical treatment
Speaker: Associate Professor L. Friberg (Stockholm, SE)
Event: ESC Congress 2016

Congress Presentation

About the speaker

Associate Professor Leif Friberg

Friberg Research, Stockholm (Sweden)
1 presentation
0 follower

4 more presentations in this session

State of the art in bleeding risk in atrial fibrillation.

Speaker: Professor I. Van Gelder (Groningen, NL)

Access
Slides
Video
Thumbnail

Bleeding risk for non-valvular AF patients prescribed warfarin, or standard doses of apixaban 5mg BID, dabigatran 150mg BID or rivaroxaban 20mg QD in real-world practice: Findings from EHR

Speaker: Doctor G. Lip (Liverpool, GB)

Access
Abstract
Slides
Video
Thumbnail

Factors associated with quality of anticoagulation control in patients with atrial fibrillation and risk of stroke and bleeding

Speaker: Mr A. Nissen Bonde (Gentofte, DK)

Access
Abstract
Slides
Video
Thumbnail

Future direction for research in antithrombotic therapy in atrial fibrillation.

Speaker: Professor E. Hylek (Boston, US)

Access
Slides
Video
Thumbnail

Access the full session

Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?

Speakers: Associate Professor L. Friberg, Professor I. Van Gelder, Doctor G. Lip, Mr A. Nissen Bonde, Professor E. Hylek
Access
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb